Marvel Biosciences has publshed a pres releaes regarding the MB-207 efficacy evaluation study for liver fibrosis we have provied

  • 2021.11.24

Marvel Biosciences, which is our client, has announced the results of pharmacology study using a STAM™ mouse model.


For detail information, see the Marvel's press release.

Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash | MARVEL Biotechnology